Previous 10 | Next 10 |
home / stock / eypt / eypt articles
U.S. stocks traded lower midway through trading, with the Dow Jones index falling over 100 points on Monday. The Dow traded down 0.36% to 36,116.18...
U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 100 points on Monday. Following the market opening Monday, the Dow tr...
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) announced topline results of its Phase 2 DAVIO 2 trial of EYP-1901, an investigational sustained d...
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) reported Q3 revenues of $15.20 million, up from $10 million a year ago and beating the $7.52 ...
WATERTOWN, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commerci...
WATERTOWN, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a pharmaceutical company committed to developi...
WATERTOWN, Mass., Oct. 25, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commerci...
– Stuart Duty appointed to EyePoint's Board of Directors – – George Elston promoted to Executive Vice President – WATERTOWN, Ma...
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) announced interim masked safety data for its lead product candidate EYP-1901 from its ongoing Phas...
News, Short Squeeze, Breakout and More Instantly...
EyePoint Pharmaceuticals Inc. Company Name:
EYPT Stock Symbol:
NASDAQ Market:
EyePoint Pharmaceuticals Inc. Website:
– Two New Independent Directors, Stuart Duty and Andrew Saik, Appointed – Third New Independent Director to Be Appointed to Board in Near Term MONTREAL and CHARLOTTE, N.C., July 15, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) (...
– Phase 3 trial design for the LUGANO and LUCIA pivotal non-inferiority trials of DURAVYU in wet AMD based on positive EOP2 meeting with FDA; on track for trial initiation in 2H 2024 – – Positive twelve-month safety and efficacy data from Phase 2 DAVIO 2 clinical tria...
WATERTOWN, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company will host an R...